BioShares Biotechnology Selected Fundamentals

BioShares Biotechnology Clinical Trials -- USA Etf  

USD 32.15  0.89  2.85%

The Macroaxis Fundamental Analysis lookup allows users to check a given indicator for any equity or select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools

Price to Earning Analysis

Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investor monitor on a daily basis. Holding a low PE stock is less risky because. When a company's profitability fall, it is likely that earnings will also go down..In other words, if you start from a lower position your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
BioShares Biotechnology 
P/E 
 = 
Market Value Per Share 
Earnings Per Share 
 = 
39.87 times

About Price to Earning

Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Compare to competition
Based on latest financial disclosure the price to earning indicator of BioShares Biotechnology Clinical Trials is roughly 39.87 times. This is 37.72% higher than that of the Bio Shares family, and 37.72% higher than that of Health category, The Price to Earning for all etfs is 383.86% lower than the firm.

BioShares Biotechnology Fundamental Drivers Relationships

BioShares Biotechnology Clinical Trials is the top ETF in price to earning as compared to similar ETFs. It is the top ETF in price to sales as compared to similar ETFs fabricating about  0.05  of Price to Sales per Price to Earning. The ratio of Price to Earning to Price to Sales for BioShares Biotechnology Clinical Trials is roughly  20.04 

Peer Comparison

BioShares Biotechnology Price to Earning Comparison
BioShares Biotechnology is currently under evaluation in price to earning as compared to similar ETFs.

Did you try this?

Run Portfolio Anywhere Now
   

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
Hide  View All  NextLaunch Portfolio Anywhere

Asset Allocation

Fund Instrument Allocation for BioShares Biotechnology
The fund invests 100.0% of asset under management in tradable equity instruments, with the rest of investments concentrated in .
 Value 
      Instrument Type 

Fundamental Indicators

Current BioShares Biotechnology financial ratios